Spin-off - ALT5 Sigma Corp
Form Type: 8-K
Filing Date: 2025-05-30
Corporate Action: Spin-off
Type: Update
Accession Number: 000162828025028621
Filing Summary: On May 21, 2025, ALT5 Sigma Corporation announced a formal separation of its healthcare assets into a new entity called Alyea Therapeutics Corporation, with a record date of June 2, 2025. The announcement elaborated on the planned scope and method of this transaction, indicating that it could occur as a split-off, spin-off, or another related transaction. The report also confirmed the identities and roles of several individuals associated with Alyea, including Dr. Amol Soin as the prospective Chief Executive Officer and several other members of the Advisory Committee with substantial experience in biotech and pharmaceuticals. The report emphasizes Alyea's mission to innovate in pain management through non-opioid solutions, leveraging the expertise of its advisory members.
Additional details:
Record Date: 2025-06-02
Healthcare Assets Name: Alyea Therapeutics Corporation
Prospective Ceo: Dr. Amol Soin
Prospective Cso: Dr. Anthony Giordano
Prospective Ccm: Mr. Russ Belden
Prospective Director: Mr. David Danziger
Prospective Director: Dr. Michael Sinclair
Prospective Chair Advisory Committee: Ms. Mary Pendergast
Prospective Ceo: Mr. Peter Tassiopoulos
Prospective Director: Mr. Tony Isaac
Form Type: 8-K
Filing Date: 2025-05-21
Corporate Action: Spin-off
Type: New
Accession Number: 000162828025027114
Filing Summary: On May 21, 2025, ALT5 Sigma Corporation announced via a press release that June 2, 2025, will be the record date for a formal separation of its healthcare assets, specifically known as Alyea Therapeutics Corporation. This transaction marks a significant strategic move by the Company to delineate its healthcare ventures from its primary operations.
Additional details:
Date Of Event: 2025-05-21
Record Date: 2025-06-02
Company Name: Alyea Therapeutics Corporation
Comments
No comments yet. Be the first to comment!